

# Cyclin Dependent Kinase 2 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/CA08DC7C426EEN.html>

Date: May 2020

Pages: 86

Price: US\$ 3,500.00 (Single User License)

ID: CA08DC7C426EEN

## Abstracts

Cyclin Dependent Kinase 2 - Pipeline Review, H1 2020

### SUMMARY

According to the recently published report 'Cyclin Dependent Kinase 2 – Pipeline Review, H1 2020'; Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) pipeline Target constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) – Cyclin-dependent kinase 2 is an enzyme encoded by the CDK2 gene. CDK2 is the catalytic subunit of the cyclin-dependent protein kinase complex which regulates progression through the cell cycle. Activity of CDK2 is especially critical during the G1 to S phase transition. CDK2 associates with and regulated by other subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A), and p27Kip1 (CDKN1B).

The report 'Cyclin Dependent Kinase 2 – Pipeline Review, H1 2020' outlays comprehensive information on the Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Currently,

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Ear Nose Throat Disorders, Metabolic Disorders and Respiratory which include indications Breast Cancer, Coronavirus Disease 2019 (COVID-19), Inflammation, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Anaplastic Astrocytoma, Colon Cancer, Cystic Fibrosis, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Hearing Disorders, Laryngeal Cancer, Mantle Cell Lymphoma, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Non-Small Cell Lung Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Pituitary ACTH Hypersecretion (Cushing Disease), Pseudomonas aeruginosa Infections, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Thymic Carcinoma, Triple-Negative Breast Cancer (TNBC) and Uterine Cancer.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)

The report reviews Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and

collaboration details & other developmental activities

The report reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects

The report assesses Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Overview

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Companies Involved in Therapeutics Development

Adastral Pharmaceuticals Inc

Apollo Therapeutics LLC

Astex Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc

G1 Therapeutics Inc

Neosome Life Sciences LLC

Pfizer Inc

Prous Institute for Biomedical Research SA

Rizen (Suzhou) Biosciences Co Ltd

Tiziana Life Sciences Plc

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Drug Profiles

AT-7519 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-68127 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fadraciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Dormant Products

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Discontinued Products

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Indications, H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020  
Number of Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Products under Development by Companies, H1 2020 (Contd..2), H1 2020  
Number of Products under Investigation by Universities/Institutes, H1 2020  
Products under Investigation by Universities/Institutes, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Pipeline by Adastral Pharmaceuticals Inc, H1 2020  
Pipeline by Apollo Therapeutics LLC, H1 2020  
Pipeline by Astex Pharmaceuticals Inc, H1 2020  
Pipeline by Cyclacel Pharmaceuticals Inc, H1 2020  
Pipeline by G1 Therapeutics Inc, H1 2020  
Pipeline by Neosome Life Sciences LLC, H1 2020  
Pipeline by Pfizer Inc, H1 2020  
Pipeline by Prous Institute for Biomedical Research SA, H1 2020  
Pipeline by Rizen (Suzhou) Biosciences Co Ltd, H1 2020  
Pipeline by Tiziana Life Sciences Plc, H1 2020  
Dormant Products, H1 2020  
Dormant Products, H1 2020 (Contd..1), H1 2020  
Dormant Products, H1 2020 (Contd..2), H1 2020  
Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

### COMPANIES MENTIONED

Adastral Pharmaceuticals Inc

Apollo Therapeutics LLC

Astex Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc

G1 Therapeutics Inc

Neosome Life Sciences LLC

Pfizer Inc

Prous Institute for Biomedical Research SA

Rizen (Suzhou) Biosciences Co Ltd

Tiziana Life Sciences Plc



## I would like to order

Product name: Cyclin Dependent Kinase 2 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/CA08DC7C426EEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA08DC7C426EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970